Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 926

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 926
---
 its net operating loss carryforwards and other tax attributes to offset income may be limited. The Company has not completed a study to assess whether an ownership changed has occurred or whether there have been multiple ownership changes.

F-111

TABLE OF CONTENTS

11. Income Taxes (continued) The Company files income tax returns in the US federal and Texas. Therefore, the Company is subject to tax examination by various US taxing authorities. The Company is not currently under examination, and is not aware of any issues under review that could result in significant payments, accruals or material deviation from its tax positions. As of December 31, 2023, tax years from 2020 to present remain open to examination by the Company’s relevant taxing jurisdictions. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period. The calculation and assessment of the Company’s income tax exposures generally involve the uncertainties in the application of complex tax laws and regulations for US federal and state jurisdictions. A tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation, on the basis of the technical merits. As of December 31, 2023, the Company has not recorded any liabilities or interest and penalties related to uncertain tax positions in its financial statements. The Company recognizes accrued interest and penalties, if any, related to uncertain tax positions in tax expense in its financial statements. 12. Net Loss Per Share Basis and diluted net loss per share attributable to common stockholders was calculated as follows (dollar amounts in thousands):

| ​                                                                        
 ​                                                                        | ​ 
 ​ | ​ 
 ​ | For the Year EndedDecember 31, 
 2023                           |   |            |   | ​ | ​ | 2022 |   |            |   | ​ 
 ​ |
|:-------------------------------------------------------------------------|:--|:--|:-------------------------------|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Numerator:                                                               | ​ | ​ | ​                              | ​ |          ​ | ​ | ​ | ​ | ​    | ​ |          ​ | ​ | ​ |
| Net loss attributable to common stockholders                             | ​ | ​ | ​                              | $ |    -17